Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

From 1 July, the weight-loss drug Wegovy will become available from Belgian pharmacists on prescription. This means Wegovy is ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting ...